Renaissance Technologies LLC Has $1.44 Million Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Renaissance Technologies LLC grew its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 166.9% in the 4th quarter, Holdings Channel reports. The fund owned 82,190 shares of the medical device company’s stock after buying an additional 51,399 shares during the period. Renaissance Technologies LLC’s holdings in Orthofix Medical were worth $1,435,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Orthofix Medical by 244.1% during the 4th quarter. JPMorgan Chase & Co. now owns 290,351 shares of the medical device company’s stock worth $5,070,000 after purchasing an additional 205,972 shares in the last quarter. Emerald Advisers LLC grew its stake in shares of Orthofix Medical by 12.2% during the fourth quarter. Emerald Advisers LLC now owns 822,377 shares of the medical device company’s stock worth $14,359,000 after buying an additional 89,717 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Orthofix Medical during the fourth quarter worth $1,286,000. Teacher Retirement System of Texas increased its holdings in shares of Orthofix Medical by 90.0% during the fourth quarter. Teacher Retirement System of Texas now owns 135,009 shares of the medical device company’s stock worth $2,357,000 after buying an additional 63,939 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Orthofix Medical in the 4th quarter valued at $1,003,000. Institutional investors own 89.76% of the company’s stock.

Insider Transactions at Orthofix Medical

In related news, insider Lucas Vitale sold 4,287 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $16.60, for a total value of $71,164.20. Following the transaction, the insider now owns 135,317 shares in the company, valued at $2,246,262.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jorge Andres Cedron sold 3,816 shares of the company’s stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $13.31, for a total transaction of $50,790.96. Following the sale, the insider now directly owns 42,500 shares in the company, valued at $565,675. This trade represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,242 shares of company stock worth $141,710. Company insiders own 2.60% of the company’s stock.

Orthofix Medical Trading Down 0.5 %

NASDAQ OFIX opened at $14.12 on Tuesday. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $550.99 million, a PE ratio of -4.51 and a beta of 0.99. The business’s 50-day moving average price is $15.67 and its two-hundred day moving average price is $17.10.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on OFIX. Roth Mkm restated a “buy” rating and set a $22.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. Finally, StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.33.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.